Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.64 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | PPARA | Q07869 | 2/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PTGIR | P43119 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049768 | 0.84 | LMNA (0.62) | ALOX15PPARAPPARGLMNAPTPN7 | |
| SCHEMBL4465276 | 0.84 | LMNA (0.62) | PLA2G10PLA2G2AALOX15PPARAPPARG | |
| SCHEMBL20832630 | 0.84 | KMT2A (0.55) | PLA2G10PLA2G2APPARAPPARGLMNA | |
| SCHEMBL5004504 | 0.84 | ALOX15 (0.70) | ALOX15PPARAPPARGLMNAPTPN7 | |
| SCHEMBL2769715 | 0.83 | PPARA (0.74) | ALOX15PPARAPPARGLMNAPTPN7 | |
| SCHEMBL413254 | 0.83 | LMNA (0.81) | ALOX15PPARAPPARGLMNAPTPN7 | |
| SCHEMBL22237436 | 0.83 | ALDH1A1 (0.69) | PLA2G10PLA2G2APPARG | |
| SCHEMBL2936246 | 0.83 | PPARA (0.60) | PLA2G10PLA2G2AALOX15PPARAPPARG | |
| SCHEMBL2774848 | 0.83 | NR4A2 (0.66) | ALOX15PPARGLMNAPTPN7FFAR1 | |
| SCHEMBL9791647 | 0.83 | PPARA (0.60) | PLA2G10PLA2G2AALOX15PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299354-B1 | FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-7414063-B2 | Inhibitors of Akt (protein kinase B) | ELI LILLY AND COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| EP-1162194-A1 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2001-12-12 | — | — | EP | disclosed |
| US-6291432-B1 | (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. | JAPAN ENERGY CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0900566-A1 | NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS | JAPAN ENERGY CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043040-A1 | Inhibitors of akt (protein kinase b) | AKT1, AKT2, BRAF | PLA2G10 3879/4885PLA2G2A 3108/4885ALOX15 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.